abstract: BACKGROUND: Labia minora reduction (labioplasty, labiaplasty) is the most common female genital aesthetic procedure. The majority of labia reductions are performed by trimming the labial edges. Many of these @entity0 present with (1) asymmetry; (2) scalloping of the labial edges with wide, occasionally painful @entity2 ; and (3) abrupt termination and distortion of the clitoral hood at its normal junctions with the clitoral frenula and the upper labium. Reconstruction can usually be performed with wedge excisions, labial YV advancement, and touch-up trimming. Reconstruction of a labial amputation, however, required the development of a new clitoral hood flap. METHODS: Twenty-four clitoral hood flaps were performed on 17 @entity0 from June of 2006 through May of 2010. An island clitoral hood flap randomly based on the dartos fascia of the lower clitoral hood and medial labium majus is transposed to the ipsilateral labial defect to reconstruct a labium. Of the 10 @entity0 with unilateral flaps, nine of the @entity0 had previous bilateral labial reductions. Reconstruction of the opposite side in these nine @entity0 was performed using one or a combination of the following: wedge excisions, @entity1 , or controlled touch-up trimming. RESULTS: All 24 flaps survived, with four minor complications. Five @entity0 underwent revision of a total of seven flaps, but only two were for complications. As experience increased, revisions for aesthetic improvement became less common. CONCLUSION: Reconstruction of labia minora defects secondary to trimming labia reductions is very successful using a combination of clitoral hood flaps, wedge excisions, and YV advancements.

title: Labia minora reconstruction using clitoral hood flaps, wedge excisions, and XXXX .

answer: @entity1


abstract: BACKGROUND: @entity2 frequently occur after @entity3 ( @entity3 ). Cardiac troponin (cTn) is a preferred biomarker for the diagnosis of @entity2 , and the clinical significance of cTn elevation after @entity3 remains controversial. This meta-analysis was performed to assess the association between cTn elevation and @entity0 outcomes, including delayed @entity4 (DCI), poor outcome ( @entity1 or dependency), and @entity1 in @entity3 @entity0 . METHODS: PubMed, Embase, and the Cochrane Library were searched for observational studies reporting an association between cTn elevation and outcome after @entity3 that were published before December 31, 2014. We extracted data regarding @entity0 characteristics, cTn elevation, and outcome measurements (DCI, poor outcome, or @entity1 ). Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. RESULTS: Twelve studies involving 2214 @entity0 were included in data analysis. Elevation of cTn was observed in 30% of the @entity0 . The cTn elevation was associated with an increased risk of DCI (RR, 1.48; 95% CI, 1.23-1.79), poor outcome (RR, 1.91; 95% CI, 1.51-2.40), and @entity1 (RR, 2.53; 95% CI, 2.04-3.12). At the 3- and 12-  month follow-ups, cTn elevation was associated with higher rates of DCI (RR, 1.51; 95% CI, 1.11-2.07), poor outcome (RR, 1.91; 95% CI, 1.51-2.40), and @entity1 (RR, 2.78; 95% CI, 1.80-4.29). At in-hospital follow-ups, cTn elevation was also associated with the higher rate of @entity1 (RR, 2.33; 95% CI, 1.76-3.07). CONCLUSIONS: cTn elevation in @entity3 @entity0 is associated with an increased risk of DCI, poor outcome, and @entity1 after @entity3 .

title: Cardiac Troponin Elevation and Outcome after XXXX : A Systematic Review and Meta-analysis.

answer: @entity3


abstract: AIM: The aim of this paper was to evaluate correlation between cyst recurrence and some cyst characteristics after sclerotherapy of non-neoplastic @entity2 with @entity6 - @entity8 combination. METHODS: Fifty two cases of simple @entity2 were subjected to sclerotherapy with @entity6 and @entity8 . Two @entity0 were excluded due to suspicious cytologic result. All @entity0 were followed-up monthly with color Doppler ultrasonography for over 12 months. Failure of procedure was considered if recurrent cyst diameter exceeds 5 centimeters detected by ultrasound. Cyst size, volume and color of aspirate, @entity5 hormone, and @entity1 marker levels of the cyst fluid were correlated to the recurrence rate. RESULTS: The fluid of cyst was serous in 32 cases and dark @entity9 -colored in twenty cases. Cytological analyses of thirty cysts were acellular sediment, twenty were suitable with @entity3 and two were reported as suspicious. At 12-month follow-up, 12 cyst recurrences was detected. There was no difference in aspirated cyst volume, cyst size and FSH and LH content of recurrent and resolved cyst. The cyst wall thickness of recurrent cyst was higher than that of resolved cyst (P<0.001). The mean @entity4 and @entity7 concentrations of resolved cysts were significantly higher than that of recurrent cysts on the other hand, the mean @entity10 levels in recurrent cysts (347.9  204.4) was significantly higher as compared to the mean @entity10 concentrations of resolved cyst (16.75  22.45). CONCLUSION: Aspiration and sclerotherapy with @entity6 and @entity8 yielded a relatively high recurrence rate in cyst with a bloody aspirate and high @entity10 levels in cyst fluid.

title: Recurrence of XXXX after sclerotherapy.

answer: @entity2


abstract: PURPOSE: The aims of this study were to develop a simplified, safe, and cost-effective peripheral-blood progenitor-cell (PBPC) mobilization protocol. @entity0 AND METHODS: Twenty-six @entity0 with relapsed or resistant @entity1 were entered onto a sequential cohort study in which schedules of various @entity3 ( @entity3 ) were administered after @entity2 1.5 g/m2. Hematologic recovery after high-dose @entity8 ( @entity8 ) @entity7 , @entity6 , and @entity9 (BEAM) chemotherapy was compared with that of 46 @entity0 who received autologous bone marrow transplantation (ABMT) without growth factors and 28 @entity0 who received ABMT followed by @entity3 . RESULTS: When @entity3 (10 micrograms/kg/d) was administered from the day after the @entity2 , @entity4 developed on day 8 followed by an abrupt increase in the WBC count. The optimal time for PBPC harvesting was the day on which the postnadir WBC count was greater than 8.0 x 10(9)/L, as shown by @entity5 + cell counts and granulocytic-macrophage colony-forming cell (GM-CFC) assays. The reproducibility of the response was such that routine monitoring of @entity5 + cell counts and GM-CFC was not necessary. A single leukapheresis on this day was adequate for prompt hematologic engraftment, and posttransplant @entity3 made little further impact on the rapid recovery. Compared with both control groups, the use of PBPC led to more rapid neutrophil recovery, markedly accelerated platelet recovery, less use of antimicrobial agents and parenteral nutrition, and more than 10 days earlier discharge from hospital. All of these differences were highly significant (P < .01). CONCLUSION: A simplified mobilization protocol is described that requires only one apheresis to achieve rapid hematologic engraftment.

title: Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated @entity0 with XXXX .

answer: @entity1


abstract: PURPOSE: The aims of this study were to develop a simplified, safe, and cost-effective peripheral-blood progenitor-cell (PBPC) mobilization protocol. @entity0 AND METHODS: Twenty-six @entity0 with relapsed or resistant @entity1 were entered onto a sequential cohort study in which schedules of various @entity3 ( @entity3 ) were administered after @entity2 1.5 g/m2. Hematologic recovery after high-dose @entity8 ( @entity8 ) @entity7 , @entity6 , and @entity9 (BEAM) chemotherapy was compared with that of 46 @entity0 who received autologous bone marrow transplantation (ABMT) without growth factors and 28 @entity0 who received ABMT followed by @entity3 . RESULTS: When @entity3 (10 micrograms/kg/d) was administered from the day after the @entity2 , @entity4 developed on day 8 followed by an abrupt increase in the WBC count. The optimal time for PBPC harvesting was the day on which the postnadir WBC count was greater than 8.0 x 10(9)/L, as shown by @entity5 + cell counts and granulocytic-macrophage colony-forming cell (GM-CFC) assays. The reproducibility of the response was such that routine monitoring of @entity5 + cell counts and GM-CFC was not necessary. A single leukapheresis on this day was adequate for prompt hematologic engraftment, and posttransplant @entity3 made little further impact on the rapid recovery. Compared with both control groups, the use of PBPC led to more rapid neutrophil recovery, markedly accelerated platelet recovery, less use of antimicrobial agents and parenteral nutrition, and more than 10 days earlier discharge from hospital. All of these differences were highly significant (P < .01). CONCLUSION: A simplified mobilization protocol is described that requires only one apheresis to achieve rapid hematologic engraftment.

title: Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated XXXX with @entity1 .

answer: @entity0


abstract: An IgG1 monoclonal antibody (mAb), designated as 15F1.5, was generated against surface determinants of a @entity1 peripheral blood-derived PHA-induced @entity5 -dependent T cell line. It reacted with 65-80% of peripheral blood mononuclear cells (PBMCs), 90-95% of polymorphonuclear cells (PMNs), 65-70% of thymocytes, 85-95% of @entity4 positive cells and 85-95% of @entity5 -dependent T lymphoid cells in flow cytometry. It was nonreactive with peripheral blood red cells and platelets. It immunoprecipitated 95 and 150 Kd proteins derived from detergent solubilized lymphocyte membranes. Indirect immunofluorescent and immunoperoxidase staining of frozen tissue sections demonstrated positive reactivity to cells in lymphoid but not nonlymphoid tissues. The 15F1.5 antibody was not directly mitogenic for PBMC's. It caused significant decrease (P < or = 0.05) in the lymphoproliferative response to T-dependent B cell mitogens, such as pokeweed mitogen (PWM) and staphage lysate (SPL), without significant effects on responses to the T cell mitogens, phytohemagglutinin (PHA), and concanavalin A (Con A). The mixed lymphocyte culture (MLC) response and both the proliferative and effector arms of the cell-mediated @entity0 reactions (CMC) were inhibited in a dose-dependent manner. The mAb also inhibited the auto- and allolymphoproliferative reactivity of mixed lymphocyte kidney or islet cell cultures (MLKC and MLIC), and the adhesion of T lymphoblasts and @entity2 -treated PMNs to endothelial cells. In vivo administration of the 15F1.5 (20 mg/day for 5 days) caused an immediate and prolonged reduction in MLC responses, associated with cell binding of the mAb to PBMC and epitope modulation during the course of treatment, as indicated by flow cytometry. These results suggest that 15F1.5 is an immunomodulating antibody reacting with @entity1 LFA-1. Thus, this mAb would be useful in studying the role of LFA-1/ @entity3 in graft rejection as well as other inflammatory responses. It would also allow the use of an animal model to investigate the immunoregulatory effects of in vivo administration of anti-CD11/CD18 antibodies in organ/tissue transplants.

title: Characterization of a monoclonal antibody recognizing an epitope designated as XXXX leukocyte-associated antigen.

answer: @entity1


abstract: The dynamics of insulin release were investigated in vitro in order to determine the regulatory processes governing its biphasic shape. When subjected to a square wave @entity2 stimulation, the isolated perfused @entity0 pancreas responded with typical biphasic insulin release. Both the duration of the nadir between the two phases and the slope of recovery of insulin release during second-phase secretion exhibited @entity2 dose dependency. Successive 40-min stimuli with @entity2 (8.3 and 16.7 mM), separated by a 20-min rest period, resulted in 2.6- 3.3-fold potentiation of the early phase insulin release rate, previously described as @entity2 -primed @entity3 ( @entity3 ) of insulin secretion. A linear relationship (r = 0.89, P less than 0.001) was observed between the degree of @entity3 and the slope of second-phase insulin release. Successive short stimuli with @entity2 (5-10 min long, 5-10 min apart; 6.9, 8.3, and 16.7 mM) resulted in the inhibition of the response to the second stimulus; this effect was termed @entity3 ( @entity3 ) of insulin release. @entity1 also induced @entity3 ; this was completely overcome by synergistic interaction with @entity2 (8.3 mM). The @entity2 - @entity1 interaction was utilized to demonstrate that the interphasic nadir of insulin release was the expression of @entity3 . Thus, introduction of an @entity1 stimulus during the nadir in @entity2 -induced insulin release abolished the silent phase, the secretion rate reaching the level expected for the combined @entity2 - @entity1 stimulus. However, the continued presence of @entity3 could be demonstrated by removal of the @entity1 stimulus, at which time, despite ongoing @entity2 stimulation, insulin secretion was markedly inhibited. These observations support the concept that the biphasic dynamics of insulin release is the net expression of three regulatory processes: 1) the acute stimulus-secretion coupling system, best observed as the immediate, first-phase response to a stimulus; 2) @entity3 of insulin release, a relatively rapid signal responsible for the silent period; and 3) @entity3 of insulin release, a slow rising signal responsible for recovery from the silent phase, building up the second-phase of secretion.

title: Biphasic insulin release as the expression of combined inhibitory and potentiating effects of XXXX .

answer: @entity2


abstract: The @entity6 @entity4 ( @entity5 ) was used to study the effects of protein kinase C activation on stimulus-secretion coupling in @entity0 pancreatic B-cells. At a nonstimulatory concentration of @entity3 (3 mM), 100 nM @entity5 , but not 10 nM @entity5 , slightly and slowly increased insulin release and 45Ca2+ efflux and decreased 86Rb+ efflux, but did not affect the membrane potential of B-cells. At a threshold concentration of @entity3 (7 mM), 100 nM @entity5 markedly increased insulin release without triggering electrical activity in B-cells. At a stimulatory concentration of @entity3 (10 mM), @entity5 caused a dose-dependent irreversible increase in insulin release, 45Ca2+ efflux, and 86Rb+ efflux and slightly augmented islet @entity2 levels. Omission of extracellular @entity1 abolished the effects of 10 nM @entity5 and partially inhibited those of 100 nM @entity5 on insulin release and 45Ca2+ efflux. In contrast, their effect on 86Rb+ efflux was paradoxically augmented. @entity3 -induced electrical activity in B-cells was only marginally affected by @entity5 ; the duration of the slow waves with spikes was not modified, but a small shortening of the polarized intervals raised their frequency and slightly increased the overall activity. This increase was significant only with 10 nM @entity5 , whereas only 100 nM @entity5 brought about a minute increase in 45Ca2+ influx. These results thus show that @entity5 induces insulin release or potentiates @entity3 -induced insulin release without mimicking or amplifying the initial ionic and electrical signals triggered by @entity3 . They suggest that protein kinase C activation affects stimulus-secretion coupling by modulating intracellular and/or nonelectrogenic membrane events.

title: The ionic, electrical, and secretory effects of protein kinase C activation in @entity0 pancreatic B-cells: studies with a XXXX .

answer: @entity6


abstract: The @entity6 @entity4 ( @entity5 ) was used to study the effects of protein kinase C activation on stimulus-secretion coupling in @entity0 pancreatic B-cells. At a nonstimulatory concentration of @entity3 (3 mM), 100 nM @entity5 , but not 10 nM @entity5 , slightly and slowly increased insulin release and 45Ca2+ efflux and decreased 86Rb+ efflux, but did not affect the membrane potential of B-cells. At a threshold concentration of @entity3 (7 mM), 100 nM @entity5 markedly increased insulin release without triggering electrical activity in B-cells. At a stimulatory concentration of @entity3 (10 mM), @entity5 caused a dose-dependent irreversible increase in insulin release, 45Ca2+ efflux, and 86Rb+ efflux and slightly augmented islet @entity2 levels. Omission of extracellular @entity1 abolished the effects of 10 nM @entity5 and partially inhibited those of 100 nM @entity5 on insulin release and 45Ca2+ efflux. In contrast, their effect on 86Rb+ efflux was paradoxically augmented. @entity3 -induced electrical activity in B-cells was only marginally affected by @entity5 ; the duration of the slow waves with spikes was not modified, but a small shortening of the polarized intervals raised their frequency and slightly increased the overall activity. This increase was significant only with 10 nM @entity5 , whereas only 100 nM @entity5 brought about a minute increase in 45Ca2+ influx. These results thus show that @entity5 induces insulin release or potentiates @entity3 -induced insulin release without mimicking or amplifying the initial ionic and electrical signals triggered by @entity3 . They suggest that protein kinase C activation affects stimulus-secretion coupling by modulating intracellular and/or nonelectrogenic membrane events.

title: The ionic, electrical, and secretory effects of protein kinase C activation in XXXX pancreatic B-cells: studies with a @entity6 .

answer: @entity0


abstract: @entity7 ( @entity9 ) is a well-known anti- @entity6 and mood stabilizing drug. A growing number of reports demonstrate that @entity9 is neuroprotective against various insults. Despite intensive efforts to develop new therapeutics for @entity4 over the past two decades, all treatments have thus far failed to show clinical effect because of treatment-limiting side effects of the drugs. Therefore, a safety-validated drug like @entity9 would be an attractive candidate if it has neuroprotective effects against @entity3 insults. The present study was undertaken to examine whether pre- and post-insult treatments with @entity9 protect against @entity11 and @entity2 in @entity1 transient (tMCAO) and permanent @entity10 (pMCAO) models. In the tMCAO (2 hr MCAO and 22 hr reperfusion) model, intraperitoneal injection of @entity9 (300 mg/kg, i.p.) 30 min prior to MCAO significantly reduced the @entity8 size and the @entity2 . @entity9 treatment immediately after reperfusion significantly reduced the @entity8 size. The administration of @entity9 at 4 hr after reperfusion failed to reduce the @entity8 size and the @entity2 . In the pMCAO model, treatment with @entity9 (300 mg/kg, i.p.) 30 min prior to MCAO significantly attenuated the @entity8 size, but did not affect the @entity2 . Western blot analysis of acetylated H3 and H4 protein levels in extracts from the @entity3 cortical area showed that treatment with @entity9 increased the expression of acetylated H3 and H4 at 2 hrs after MCAO. These results demonstrated that treatment with @entity9 prior to @entity3 attenuated @entity3 @entity5 in both @entity1 tMCAO and pMCAO models and treatment with @entity9 immediately after reperfusion reduced the @entity8 area in the tMCAO model. @entity9 could therefore be evaluated for clinical use in @entity4 @entity0 .

title: Neuroprotection by XXXX in @entity1 models of permanent and transient focal cerebral ischemia.

answer: @entity7


abstract: @entity7 ( @entity9 ) is a well-known anti- @entity6 and mood stabilizing drug. A growing number of reports demonstrate that @entity9 is neuroprotective against various insults. Despite intensive efforts to develop new therapeutics for @entity4 over the past two decades, all treatments have thus far failed to show clinical effect because of treatment-limiting side effects of the drugs. Therefore, a safety-validated drug like @entity9 would be an attractive candidate if it has neuroprotective effects against @entity3 insults. The present study was undertaken to examine whether pre- and post-insult treatments with @entity9 protect against @entity11 and @entity2 in @entity1 transient (tMCAO) and permanent @entity10 (pMCAO) models. In the tMCAO (2 hr MCAO and 22 hr reperfusion) model, intraperitoneal injection of @entity9 (300 mg/kg, i.p.) 30 min prior to MCAO significantly reduced the @entity8 size and the @entity2 . @entity9 treatment immediately after reperfusion significantly reduced the @entity8 size. The administration of @entity9 at 4 hr after reperfusion failed to reduce the @entity8 size and the @entity2 . In the pMCAO model, treatment with @entity9 (300 mg/kg, i.p.) 30 min prior to MCAO significantly attenuated the @entity8 size, but did not affect the @entity2 . Western blot analysis of acetylated H3 and H4 protein levels in extracts from the @entity3 cortical area showed that treatment with @entity9 increased the expression of acetylated H3 and H4 at 2 hrs after MCAO. These results demonstrated that treatment with @entity9 prior to @entity3 attenuated @entity3 @entity5 in both @entity1 tMCAO and pMCAO models and treatment with @entity9 immediately after reperfusion reduced the @entity8 area in the tMCAO model. @entity9 could therefore be evaluated for clinical use in @entity4 @entity0 .

title: Neuroprotection by @entity7 in XXXX models of permanent and transient focal cerebral ischemia.

answer: @entity1


abstract: A serial neurophysiological study has been performed of 2 @entity0 during the clinical course of @entity2 after @entity0 growth hormone (hGH) treatment. Evolution of the EEG pattern was typical: slow waves, periodic sharp wave complexes, then extinction. VEP components were moderately altered. BAERs performed in only 1 @entity0 were normal. The blink reflex (BR) showed an early alteration of the R1 component. The @entity3 exhibited early and profound anomalies. Pathological changes were obvious at the first recording, at the beginning of the second month after clinical onset: increase in peak latencies, morphological changes and important reduction of b wave amplitude (a/b amplitude ratio > or = 0.70; normal range 0.27-0.41). The @entity3 was completely absent a few months later. These results are compared with the similar @entity1 described in @entity2 - or scrapie-infected rodents. In the 2 @entity0 , pathological changes in @entity3 and in BR were obvious several months before the development of the typical EEG pattern. Therefore, early @entity3 and BR recording can be helpful in the diagnosis of @entity2 , especially in this ataxic form following hGH treatment.

title: Neurophysiological follow-up in two @entity0 with XXXX after @entity0 growth hormone treatment.

answer: @entity2


abstract: A serial neurophysiological study has been performed of 2 @entity0 during the clinical course of @entity2 after @entity0 growth hormone (hGH) treatment. Evolution of the EEG pattern was typical: slow waves, periodic sharp wave complexes, then extinction. VEP components were moderately altered. BAERs performed in only 1 @entity0 were normal. The blink reflex (BR) showed an early alteration of the R1 component. The @entity3 exhibited early and profound anomalies. Pathological changes were obvious at the first recording, at the beginning of the second month after clinical onset: increase in peak latencies, morphological changes and important reduction of b wave amplitude (a/b amplitude ratio > or = 0.70; normal range 0.27-0.41). The @entity3 was completely absent a few months later. These results are compared with the similar @entity1 described in @entity2 - or scrapie-infected rodents. In the 2 @entity0 , pathological changes in @entity3 and in BR were obvious several months before the development of the typical EEG pattern. Therefore, early @entity3 and BR recording can be helpful in the diagnosis of @entity2 , especially in this ataxic form following hGH treatment.

title: Neurophysiological follow-up in two XXXX with @entity2 after @entity0 growth hormone treatment.

answer: @entity0


abstract: A serial neurophysiological study has been performed of 2 @entity0 during the clinical course of @entity2 after @entity0 growth hormone (hGH) treatment. Evolution of the EEG pattern was typical: slow waves, periodic sharp wave complexes, then extinction. VEP components were moderately altered. BAERs performed in only 1 @entity0 were normal. The blink reflex (BR) showed an early alteration of the R1 component. The @entity3 exhibited early and profound anomalies. Pathological changes were obvious at the first recording, at the beginning of the second month after clinical onset: increase in peak latencies, morphological changes and important reduction of b wave amplitude (a/b amplitude ratio > or = 0.70; normal range 0.27-0.41). The @entity3 was completely absent a few months later. These results are compared with the similar @entity1 described in @entity2 - or scrapie-infected rodents. In the 2 @entity0 , pathological changes in @entity3 and in BR were obvious several months before the development of the typical EEG pattern. Therefore, early @entity3 and BR recording can be helpful in the diagnosis of @entity2 , especially in this ataxic form following hGH treatment.

title: Neurophysiological follow-up in two @entity0 with @entity2 after XXXX growth hormone treatment.

answer: @entity0


abstract: An intensive 7-day combination chemotherapy protocol was designed to reinduce @entity0 with early bone @entity5 of @entity10 (less than 6 months after the end of or during preceding treatment). This aggressive approach seemed to be justified for a group of @entity0 who were at the highest risk for ultimate treatment failure. In all, 38 @entity0 were enrolled for study. The ratio of male (median age, 10 years) to female (median age, 13 years) subjects was 27:11. Thirty @entity0 were treated for their first relapse and eight for their second or subsequent relapse. Isolated bone marrow involvement was present in 24 cases. All @entity0 had received heavy pretreatment including @entity12 with cumulative doses of between 120 and 240 mg/m2. 22 of these @entity0 , achieved complete remission, ten did not respond to therapy, and six died from the @entity1 of the protocol. @entity9 was the cause of @entity3 in one @entity0 (after additional radiotherapy for a mediastinal mass). No further clinical manifestation of @entity6 could be observed. The other five @entity0 died from @entity8 or @entity2 complications. The main side effects were @entity4 , @entity7 , @entity11 , and severe @entity5 lasting for about 2 weeks with nadirs of platelets and white blood count around days 10-14. The remission rate of 60% was acceptable, though not satisfactory. Only four @entity0 survived disease-free for 13+, 14+, 20+, and 22+ months after diagnosis of relapse.

title: Aggressive combination chemotherapy of bone @entity5 in childhood XXXX containing aclacinomycin-A: a multicentric trial.

answer: @entity10


abstract: An intensive 7-day combination chemotherapy protocol was designed to reinduce @entity0 with early bone @entity5 of @entity10 (less than 6 months after the end of or during preceding treatment). This aggressive approach seemed to be justified for a group of @entity0 who were at the highest risk for ultimate treatment failure. In all, 38 @entity0 were enrolled for study. The ratio of male (median age, 10 years) to female (median age, 13 years) subjects was 27:11. Thirty @entity0 were treated for their first relapse and eight for their second or subsequent relapse. Isolated bone marrow involvement was present in 24 cases. All @entity0 had received heavy pretreatment including @entity12 with cumulative doses of between 120 and 240 mg/m2. 22 of these @entity0 , achieved complete remission, ten did not respond to therapy, and six died from the @entity1 of the protocol. @entity9 was the cause of @entity3 in one @entity0 (after additional radiotherapy for a mediastinal mass). No further clinical manifestation of @entity6 could be observed. The other five @entity0 died from @entity8 or @entity2 complications. The main side effects were @entity4 , @entity7 , @entity11 , and severe @entity5 lasting for about 2 weeks with nadirs of platelets and white blood count around days 10-14. The remission rate of 60% was acceptable, though not satisfactory. Only four @entity0 survived disease-free for 13+, 14+, 20+, and 22+ months after diagnosis of relapse.

title: Aggressive combination chemotherapy of bone XXXX in childhood @entity10 containing aclacinomycin-A: a multicentric trial.

answer: @entity5


abstract: Two pathogenic mechanisms of @entity3 @entity2 are discussed, one involving bacterial exoenzymes, the other involving polymorphonuclear leukocyte (PMN)-derived lysosomal enzymes. The objective of the present study was (1) to show the relative importance of the two mechanisms and (2) to evaluate the effect of active immunization against @entity3 exoenzymes on @entity0 . @entity1 were immunized against @entity3 alkaline protease (AP) or elastase ( @entity6 ) and challenged with the respective enzymes. @entity0 was studied by light photography (LP). In another group, @entity1 were immunized against AP, @entity6 and exotoxin A (ExoA) and challenged with @entity3 strains PA01 or PA103. @entity0 was studied with LP, light microscopy, and electron microscopy. Immunized animals were totally protected against intracorneal inoculation of @entity3 proteases. Twelve hr and 24 hr after challenge with whole bacteria, immunized @entity1 revealed less @entity0 than non-immunized animals. However, after 48 hr @entity0 (ie severe @entity5 ) was comparable in both groups. The study suggests that @entity0 involving lysosomal enzymes from stimulated PMN is more important after @entity4 than direct damage by @entity3 exoenzymes.

title: Relevance of host-derived and bacterial factors in XXXX @entity2 .

answer: @entity3


abstract: Two pathogenic mechanisms of @entity3 @entity2 are discussed, one involving bacterial exoenzymes, the other involving polymorphonuclear leukocyte (PMN)-derived lysosomal enzymes. The objective of the present study was (1) to show the relative importance of the two mechanisms and (2) to evaluate the effect of active immunization against @entity3 exoenzymes on @entity0 . @entity1 were immunized against @entity3 alkaline protease (AP) or elastase ( @entity6 ) and challenged with the respective enzymes. @entity0 was studied by light photography (LP). In another group, @entity1 were immunized against AP, @entity6 and exotoxin A (ExoA) and challenged with @entity3 strains PA01 or PA103. @entity0 was studied with LP, light microscopy, and electron microscopy. Immunized animals were totally protected against intracorneal inoculation of @entity3 proteases. Twelve hr and 24 hr after challenge with whole bacteria, immunized @entity1 revealed less @entity0 than non-immunized animals. However, after 48 hr @entity0 (ie severe @entity5 ) was comparable in both groups. The study suggests that @entity0 involving lysosomal enzymes from stimulated PMN is more important after @entity4 than direct damage by @entity3 exoenzymes.

title: Relevance of host-derived and bacterial factors in @entity3 XXXX .

answer: @entity2


abstract: The clinical profile of pelvic @entity6 , which is being recognized with increased frequency in IUD users, can be misleading in such @entity0 and lead to dangerous delays in diagnosis. The authors present a case in which an IUD user initially sought medical attention for multiple liver abscesses secondary to spread from unsuspected @entity1 . The 43-year-old @entity0 , who was admitted with right upper @entity2 and @entity3 , had a 15-year history of IUD use, although the device had been removed 1 year prior to admission for apparent infection in the left ovary. Ultrasound revealed mixed @entity4 as well as a complex subcapsular fluid collection. A solid left adnexal mass was demonstrated in the pelvis. Computed tomography scan indicated extension of 1 of the @entity4 through the liver capsule and into the abdominal wall. Needle aspirations of the @entity4 yielded thick pus that was later identified as Actinomyces israelii. @entity6 was evident in the @entity5 . Colonization of the vagina and uterus by @entity6 has been reported by 1.6-5.3% of IUD users, and the risk appears to increase when the same IUD is used for a prolonged time period. In this case, neither the computed tomography scan nor ultrasound suggested an inflammatory process of the left ovary. Aspiration of a @entity4 under ultrasound guidance was necessary for the correct diagnosis. Since @entity6 has the potential to spread to extrapelvic organs such as the peritoneum, liver, and brain, early diagnosis is essential.

title: XXXX involving the liver. Computed tomography/ultrasound correlation.

answer: @entity6


abstract: Maternal uterine blood flow was @entity0 during total umbilical cord occlusion, probably based on an increased fetal cotyledonary tissue pressure (Hasaart and de Haan (1985) Eur. J. Obstet. Gynec. Reprod. Biol., 19, 125-131). This supposed mechanism was further analysed by performing selective occlusions of the umbilical arteries and/or veins (mean occlusion time 35 s). An occluding device which allowed separate occlusion of umbilical veins and arteries was applied to the umbilical cord in 7 chronically prepared fetal @entity3 between 106 and 135 days gestation. Median uterine artery blood flow (UBF) was measured with an electromagnetic flow meter. During occlusion of both umbilical veins (VV, n = 22) in 6 animals a maximal decrease in UBF to 87.5% of control value (P less than 0.001) was found at the end occlusion, followed by a gradual return to control value in the post occlusion period. Occlusion of both umbilical arteries ( @entity1 , n = 29) in 5 animals was accompanied by a slight increase in UBF to 103% of control value (P less than 0.01). Total occlusion of the umbilical arteries and veins simultaneously (n = 17) in 4 animals did not result in any change in UBF. The changes in volume and turgor in the fetal cotyledonary tissue associated with the arterial and @entity2 should lead to respectively @entity1 ( @entity1 ) and increase (VV) in resistance to maternal flow, causing the changes in uterine blood flow. It is concluded that volume changes in the fetal compartment of the @entity3 placenta affect maternal uterine blood flow.

title: Effect of selective occlusion of the umbilical arteries and/or veins on uterine blood flow in XXXX .

answer: @entity3


abstract: BACKGROUND: The two major types of noninvasive @entity0 , @entity4 ( @entity4 ) and @entity3 ( @entity3 ), are quite different in their histopathologic appearance and clinical implications. @entity3 is only a marker of an increased risk of later development of @entity2 , whereas most @entity4 lesions are at least nonobligate precursors of @entity2 . @entity4 is a heterogeneous group of lesions composed of several distinct subtypes, with only the comedo subtype having immediate malignant potential. The authors' purpose was to analyze noninvasive @entity2 for the presence of a gene product ( @entity5 ) indicative of a favorable prognosis in @entity2 to determine differences (1) among the different types of CIS and (2) in CIS with and without an accompanying invasive component. METHODS: Immunohistochemical methods were used to detect @entity5 gene product in archival material from two groups of @entity1 : Group 1 consisted of 54 cases of purely noninvasive @entity2 , and Group 2 consisted of 55 examples of noninvasive @entity2 associated with an invasive component. RESULTS: Among the cases of CIS with no invasion, @entity3 and comedo @entity4 expressed more @entity5 than noncomedo @entity4 (P < or = 0.03). There were no differences among these CIS subtypes in the group with invasion. Comparing subtypes of CIS in the groups with or without invasion, only comedo @entity4 was significantly different, with greater expression in the CIS group with no invasion compared with comedo @entity4 associated with an invasive component (P = 0.04). CONCLUSIONS: These results support the special nature of @entity3 and the heterogeneous nature of @entity4 . The in situ component attending an invasive component may be different from anatomically similar lesion without associated invasion. The absence of @entity5 in comedo @entity4 may be indicative of invasive capacity.

title: Heterogeneous expression of @entity5 gene product in noninvasive XXXX .

answer: @entity0


abstract: BACKGROUND: The two major types of noninvasive @entity0 , @entity4 ( @entity4 ) and @entity3 ( @entity3 ), are quite different in their histopathologic appearance and clinical implications. @entity3 is only a marker of an increased risk of later development of @entity2 , whereas most @entity4 lesions are at least nonobligate precursors of @entity2 . @entity4 is a heterogeneous group of lesions composed of several distinct subtypes, with only the comedo subtype having immediate malignant potential. The authors' purpose was to analyze noninvasive @entity2 for the presence of a gene product ( @entity5 ) indicative of a favorable prognosis in @entity2 to determine differences (1) among the different types of CIS and (2) in CIS with and without an accompanying invasive component. METHODS: Immunohistochemical methods were used to detect @entity5 gene product in archival material from two groups of @entity1 : Group 1 consisted of 54 cases of purely noninvasive @entity2 , and Group 2 consisted of 55 examples of noninvasive @entity2 associated with an invasive component. RESULTS: Among the cases of CIS with no invasion, @entity3 and comedo @entity4 expressed more @entity5 than noncomedo @entity4 (P < or = 0.03). There were no differences among these CIS subtypes in the group with invasion. Comparing subtypes of CIS in the groups with or without invasion, only comedo @entity4 was significantly different, with greater expression in the CIS group with no invasion compared with comedo @entity4 associated with an invasive component (P = 0.04). CONCLUSIONS: These results support the special nature of @entity3 and the heterogeneous nature of @entity4 . The in situ component attending an invasive component may be different from anatomically similar lesion without associated invasion. The absence of @entity5 in comedo @entity4 may be indicative of invasive capacity.

title: Heterogeneous expression of XXXX gene product in noninvasive @entity0 .

answer: @entity5


abstract: A 42-year-old @entity0 had suffered from @entity2 since April 2009. Computed tomography revealed a @entity1 with marked calcification in the left frontal lobe adjacent to the left anterior horn of the lateral ventricle. T1-weighted @entity7 -enhanced magnetic resonance imaging showed a well-enhanced @entity1 at the lesion. Dynamic @entity6 positron emission tomography showed no delayed @entity6 attenuation. Initial preoperative diagnosis was @entity10 ( @entity10 ). However, @entity8 was determined upon a second diagnosis. The @entity0 underwent @entity1 removal. @entity3 and @entity4 staining showed the characteristic fried egg-like cells, round nuclei, and immunohistochemically, the @entity1 cells were positive for glial fibrillary acidic protein, @entity9 , neuronal nuclear antigen, microtubule-associated protein 2 and @entity11 . The @entity5 labeling index was 20%, which suggested @entity1 . Although these findings demonstrated that the @entity1 had glioneuronal character, it was difficult to differentiate between @entity10 and @entity8 . There have been reports that @entity11 immunohistochemistry is generally positive in cases of @entity8 , but not in cases of @entity10 . We completed the diagnosis as @entity8 . Subsequent electron microscopy results presented oligodendroglial but not neuronal characteristics. We concluded that @entity11 is useful in the differential diagnosis of @entity8 and EVNs.

title: @entity11 is useful in the differential diagnosis of @entity8 and XXXX .

answer: @entity10


abstract: A 42-year-old @entity0 had suffered from @entity2 since April 2009. Computed tomography revealed a @entity1 with marked calcification in the left frontal lobe adjacent to the left anterior horn of the lateral ventricle. T1-weighted @entity7 -enhanced magnetic resonance imaging showed a well-enhanced @entity1 at the lesion. Dynamic @entity6 positron emission tomography showed no delayed @entity6 attenuation. Initial preoperative diagnosis was @entity10 ( @entity10 ). However, @entity8 was determined upon a second diagnosis. The @entity0 underwent @entity1 removal. @entity3 and @entity4 staining showed the characteristic fried egg-like cells, round nuclei, and immunohistochemically, the @entity1 cells were positive for glial fibrillary acidic protein, @entity9 , neuronal nuclear antigen, microtubule-associated protein 2 and @entity11 . The @entity5 labeling index was 20%, which suggested @entity1 . Although these findings demonstrated that the @entity1 had glioneuronal character, it was difficult to differentiate between @entity10 and @entity8 . There have been reports that @entity11 immunohistochemistry is generally positive in cases of @entity8 , but not in cases of @entity10 . We completed the diagnosis as @entity8 . Subsequent electron microscopy results presented oligodendroglial but not neuronal characteristics. We concluded that @entity11 is useful in the differential diagnosis of @entity8 and EVNs.

title: @entity11 is useful in the differential diagnosis of XXXX and @entity10 .

answer: @entity8


abstract: A 42-year-old @entity0 had suffered from @entity2 since April 2009. Computed tomography revealed a @entity1 with marked calcification in the left frontal lobe adjacent to the left anterior horn of the lateral ventricle. T1-weighted @entity7 -enhanced magnetic resonance imaging showed a well-enhanced @entity1 at the lesion. Dynamic @entity6 positron emission tomography showed no delayed @entity6 attenuation. Initial preoperative diagnosis was @entity10 ( @entity10 ). However, @entity8 was determined upon a second diagnosis. The @entity0 underwent @entity1 removal. @entity3 and @entity4 staining showed the characteristic fried egg-like cells, round nuclei, and immunohistochemically, the @entity1 cells were positive for glial fibrillary acidic protein, @entity9 , neuronal nuclear antigen, microtubule-associated protein 2 and @entity11 . The @entity5 labeling index was 20%, which suggested @entity1 . Although these findings demonstrated that the @entity1 had glioneuronal character, it was difficult to differentiate between @entity10 and @entity8 . There have been reports that @entity11 immunohistochemistry is generally positive in cases of @entity8 , but not in cases of @entity10 . We completed the diagnosis as @entity8 . Subsequent electron microscopy results presented oligodendroglial but not neuronal characteristics. We concluded that @entity11 is useful in the differential diagnosis of @entity8 and EVNs.

title: XXXX is useful in the differential diagnosis of @entity8 and @entity10 .

answer: @entity11


abstract: BACKGROUND: The treatment of @entity4 is a challenge for physicians and @entity0 . Although different therapeutic options have been described to date, their individual relevance has still to be defined.    METHODS: We performed a retrospective study of 61 @entity0 with a @entity3 ( @entity3 , mean age 22 years), who were referred to our depart-ment during the last 5years. The size of the @entity3 was larger than 5 cm in 41 @entity0 (66%). The lower extremities were involved in 45 cases (73%). The most frequent clinical manifestations were recurrent swelling (80%), @entity2 (63%), varicosis (60%) and @entity5 (39%). MR angiography with venous sequences was always performed before treatment. Depending on the localisation and the extension of the @entity3 , different techniques of embolisation were selected: foam sclerotherapy or application of synthetic glue by direct punction, coiling of pelvic veins or arterial embolisation with glue. RESULTS: 42 @entity0 (69%) underwent a procedure because of the complaints or the extension of the @entity3 . An embolisation was performed in 25 @entity0 with 65 interventional sessions. The most frequent technique was foam sclerotherapy (45 ), followed by glue injection (13 ), pelvic -venous coiling (6 ) and arterial embolisation with glue (1 ). Fifteen @entity0 (60%) reported a very good and 8 @entity0 a marked improvement (32%). In two cases there was no change of the complaints. The postinterventional complications were severe @entity2 (n=3) and skin/fat @entity1 at the toe of one @entity0 . CONCLUSIONS: The embolisation of @entity3 is an effective therapeutic tool. Different techniques can be used to address specific localisations and morphological patterns. The com-plication rate is very low when a step-by-step -approach is used, so that a repeat intervention is feasible. However, a more specific documentation of the post-interventional changes of the @entity3 is needed before a general recommendation can be given.

title: [The embolisation of XXXX ].

answer: @entity3


abstract: The postsynaptic density (PSD) is a specialization of the submembranous cytoskeleton that is visible in the electron microscope on the cytoplasmic face of the postsynaptic membrane. A subcellular fraction enriched in structures with the morphology of PSDs contains signal-transduction molecules thought to regulate receptor localization and function in the central nervous system. We have purified a prominent @entity2 -phosphorylated glycoprotein of apparent molecular mass 180 kDa, termed PSD-gp180, that is highly enriched in the @entity0 forebrain PSD fraction. The sequences of four tryptic peptides generated from the protein reveal that it is the 2B subunit of the @entity3 ( @entity1 ) type @entity4 receptor. We have confirmed the identity of PSD-gp180 by showing that it reacts with antibodies raised against a unique fragment of the 2B subunit of the @entity1 receptor. We also show that the 2B subunit is the most prominently @entity2 -phosphorylated protein in the PSD fraction based upon recognition by an anti- @entity5 antibody. Two types of @entity1 receptor subunits have been identified by molecular cloning [Nakanishi, S. (1992) Science 258, 597-603]. The single type 1 subunit is expressed throughout the brain and is necessary for formation of the receptor channel. The four type 2 subunits (2A, 2B, 2C, and 2D) are expressed in discrete brain regions, contain unusually long unique C termini, and confer distinct kinetic properties on @entity1 receptors that contain them. Our findings suggest that, in the forebrain, @entity1 receptor subunit 2B may serve to anchor @entity1 receptors at the postsynaptic membrane through its interaction with the PSD. The prominent presence of @entity6 further suggests that the @entity1 receptor may be regulated by @entity2 phosphorylation or that it may participate in signaling through @entity2 phosphorylation and through its ion channel.

title: The major XXXX -phosphorylated protein in the postsynaptic density fraction is @entity3 receptor subunit 2B.

answer: @entity2


abstract: The postsynaptic density (PSD) is a specialization of the submembranous cytoskeleton that is visible in the electron microscope on the cytoplasmic face of the postsynaptic membrane. A subcellular fraction enriched in structures with the morphology of PSDs contains signal-transduction molecules thought to regulate receptor localization and function in the central nervous system. We have purified a prominent @entity2 -phosphorylated glycoprotein of apparent molecular mass 180 kDa, termed PSD-gp180, that is highly enriched in the @entity0 forebrain PSD fraction. The sequences of four tryptic peptides generated from the protein reveal that it is the 2B subunit of the @entity3 ( @entity1 ) type @entity4 receptor. We have confirmed the identity of PSD-gp180 by showing that it reacts with antibodies raised against a unique fragment of the 2B subunit of the @entity1 receptor. We also show that the 2B subunit is the most prominently @entity2 -phosphorylated protein in the PSD fraction based upon recognition by an anti- @entity5 antibody. Two types of @entity1 receptor subunits have been identified by molecular cloning [Nakanishi, S. (1992) Science 258, 597-603]. The single type 1 subunit is expressed throughout the brain and is necessary for formation of the receptor channel. The four type 2 subunits (2A, 2B, 2C, and 2D) are expressed in discrete brain regions, contain unusually long unique C termini, and confer distinct kinetic properties on @entity1 receptors that contain them. Our findings suggest that, in the forebrain, @entity1 receptor subunit 2B may serve to anchor @entity1 receptors at the postsynaptic membrane through its interaction with the PSD. The prominent presence of @entity6 further suggests that the @entity1 receptor may be regulated by @entity2 phosphorylation or that it may participate in signaling through @entity2 phosphorylation and through its ion channel.

title: The major @entity2 -phosphorylated protein in the postsynaptic density fraction is XXXX receptor subunit 2B.

answer: @entity3


abstract: Administration of lipopolysaccharide (LPS) to experimental animals leads to diminished mesenteric perfusion, increased ileal mucosal [H+] , and increased gut epithelial permeability to hydrophilic solutes. We sought to determine whether these phenomena are causally related. Experiments were performed in anesthetized @entity5 . Permeability was assessed by measuring the plasma-to-lumen clearance of @entity6 dextran (4,000 Da; FD-4) by a segment of ileum perfused with Ringer lactate solution. Mucosal perfusion (Qmuc) and [H4+] were estimated using laser-Doppler flowmetry and tonometry, respectively. In an initial series of experiments, we showed that mucosal permeability was linearly correlated with mucosal [H+] in animals subjected to graded degrees of mechanically induced @entity7 (n = 14, R2 = 0.58, P < 0.002) or injected with graded doses of LPS (n = 11, R2 = 0.93, P < 0.0001). In a second series of experiments, we induced @entity0 in normal @entity5 by mechanical ventilation with either a @entity2 (n = 7) or a hypercapnic (n = 5) gas mixture. In both groups, ileal mucosal permeability to FD-4 increased significantly (P < 0.05), although transmesenteric release of @entity4 increased significantly only in the @entity2 group. Qmuc was unchanged in both groups. These data suggest that @entity0 , even in the absence of tissue @entity1 or @entity2 , increases intestinal permeability to a macromolecular hydrophilic solute. Tissue @entity3 may be an important factor contributing to LPS-induced gut @entity0 .

title: Endotoxin-induced ileal XXXX in @entity5 : role of tissue @entity3 .

answer: @entity0


abstract: Administration of lipopolysaccharide (LPS) to experimental animals leads to diminished mesenteric perfusion, increased ileal mucosal [H+] , and increased gut epithelial permeability to hydrophilic solutes. We sought to determine whether these phenomena are causally related. Experiments were performed in anesthetized @entity5 . Permeability was assessed by measuring the plasma-to-lumen clearance of @entity6 dextran (4,000 Da; FD-4) by a segment of ileum perfused with Ringer lactate solution. Mucosal perfusion (Qmuc) and [H4+] were estimated using laser-Doppler flowmetry and tonometry, respectively. In an initial series of experiments, we showed that mucosal permeability was linearly correlated with mucosal [H+] in animals subjected to graded degrees of mechanically induced @entity7 (n = 14, R2 = 0.58, P < 0.002) or injected with graded doses of LPS (n = 11, R2 = 0.93, P < 0.0001). In a second series of experiments, we induced @entity0 in normal @entity5 by mechanical ventilation with either a @entity2 (n = 7) or a hypercapnic (n = 5) gas mixture. In both groups, ileal mucosal permeability to FD-4 increased significantly (P < 0.05), although transmesenteric release of @entity4 increased significantly only in the @entity2 group. Qmuc was unchanged in both groups. These data suggest that @entity0 , even in the absence of tissue @entity1 or @entity2 , increases intestinal permeability to a macromolecular hydrophilic solute. Tissue @entity3 may be an important factor contributing to LPS-induced gut @entity0 .

title: Endotoxin-induced ileal @entity0 in XXXX : role of tissue @entity3 .

answer: @entity5


abstract: Administration of lipopolysaccharide (LPS) to experimental animals leads to diminished mesenteric perfusion, increased ileal mucosal [H+] , and increased gut epithelial permeability to hydrophilic solutes. We sought to determine whether these phenomena are causally related. Experiments were performed in anesthetized @entity5 . Permeability was assessed by measuring the plasma-to-lumen clearance of @entity6 dextran (4,000 Da; FD-4) by a segment of ileum perfused with Ringer lactate solution. Mucosal perfusion (Qmuc) and [H4+] were estimated using laser-Doppler flowmetry and tonometry, respectively. In an initial series of experiments, we showed that mucosal permeability was linearly correlated with mucosal [H+] in animals subjected to graded degrees of mechanically induced @entity7 (n = 14, R2 = 0.58, P < 0.002) or injected with graded doses of LPS (n = 11, R2 = 0.93, P < 0.0001). In a second series of experiments, we induced @entity0 in normal @entity5 by mechanical ventilation with either a @entity2 (n = 7) or a hypercapnic (n = 5) gas mixture. In both groups, ileal mucosal permeability to FD-4 increased significantly (P < 0.05), although transmesenteric release of @entity4 increased significantly only in the @entity2 group. Qmuc was unchanged in both groups. These data suggest that @entity0 , even in the absence of tissue @entity1 or @entity2 , increases intestinal permeability to a macromolecular hydrophilic solute. Tissue @entity3 may be an important factor contributing to LPS-induced gut @entity0 .

title: Endotoxin-induced ileal @entity0 in @entity5 : role of tissue XXXX .

answer: @entity3


abstract: Twenty-five @entity1 were studied with a battery of antibodies directed against keratin and @entity2 ( @entity2 ). The keratin antibody MNF 116 showed reactivity in 24 @entity0 . In addition, 22 @entity0 showed reactivity with the antibody Keratin Wide Spectrum, 20 with the antibody Keratin 56, 64, and 19 with CAM 5.2. Seventeen @entity0 showed reactivity with @entity2 . The keratin and @entity2 reactivity was present in cells lining obvious cleft-like structures in @entity0 . In the spindle cell areas of both biphasic and monophasic @entity0 , we found clusters of a few reacting cells apparently located around small clefts. In the @entity0 , clusters of @entity0 cells reactive for both the keratins and @entity2 were present. In conclusion, we found that proper identification of epithelial differentiation in @entity1 is facilitated by an immunohistochemical application of anti-epithelial antibodies. In most @entity0 , there was immunoreactivity for the same type of keratins as are normally identified in simple epithelia (the antibody CAM 5.2), but also for those found in stratified squamous epithelia (the antibody Keratin 56, 64). The results indicate that screening for epithelial features on paraffin sections in the various types of @entity1 , even the poorly differentiated @entity0 , is improved if epithelial antibodies with a broad spectrum of reactivity are chosen.

title: XXXX . An immunohistochemical study of the epithelial component.

answer: @entity1


abstract: Chemotherapy for cervical @entity1 @entity0 with recurrent and/or advanced disease has been complicated by excessive @entity2 and short duration of responses, leading to little or no improvement in survival. Modification of drug scheduling and delivery of @entity5 , @entity8 , @entity7 , and @entity6 has resulted in a new combination regimen with @entity2 and a survival advantage for responders. PBM ( @entity5 80 mg/m2 D1, @entity8 10 mu/m2/day D3-6, @entity7 150 mg/m2 D15, 22 with @entity9 ) is alternated with @entity10 ( @entity5 100 mg/m2 D1, @entity6 1000 mg/m2/day D2-5) q 4 weeks for 3-6 months. The @entity5 , @entity8 , and @entity6 were delivered by continuous infusion. Twenty-three @entity0 with recurrent and 17 with @entity1 are evaluable; 91% of @entity0 with recurrent disease had received prior radiation therapy. The response rate was 30.4% in those with recurrent disease, and 41.2% in those with advanced disease, with 86 and 42.9% of responders respectively achieving a CR. Survival data were analyzed for each group separately, as well as for the combined recurrent/advanced disease group (N = 40). The results and significance were not changed by the groupings. In the combined recurrent/advanced group, median duration of response was 10.5 months, mean 20.1, and the median overall survival was 11 months, mean 20.5 +/- 3.5. There was a survival advantage accrued to the responders (median, 28 months) vs the nonresponders (10 months) (P = 0.0005 by log rank test). Moreover, there was a significant difference in progression-free interval between responders vs nonresponders (P = 0.0001), as well as between responders and those with stable disease (P = 0.001). This regimen was very well tolerated and there was no significant @entity4 . Furthermore, in the subset of 23 @entity0 who had recurrent disease, 67% achieved palliation of @entity3 . Experience with this protocol supports the continuing use of chemotherapy in the management of cervical @entity1 @entity0 .

title: Chemotherapy of recurrent/ XXXX : results of the Yale University PBM-PFU protocol.

answer: @entity1


abstract: Previously, we demonstrated that low concentrations of @entity2 (< or = 10(-9) M) increased automaticity in neonatal but not in adult @entity0 ventricular myocardium. In the present study, we used cultured neonatal @entity0 ventricular myocytes grown alone or in the presence of dissociated sympathetic neurons as an experimental model to study the ontogeny of the muscarinic response. McN A343 (< or = 10(-9) M), an M1 selective agonist, increased spontaneous rate from 51 +/- 4 to 56 +/- 5 beats per minute (bpm), and this excitatory response was blocked by 10(-9) M @entity6 , an M1 selective antagonist, but not by the M2 selective antagonist @entity9 , nor by the alpha 1 adrenergic antagonist @entity5 and the beta adrenergic antagonist @entity3 (all 10(-7) M) In innervated myocytes, McN A343 also increased rate from 48 +/- 6 to 55 +/- 6 bpm. However, this effect was blocked by either 10(-9) M @entity6 or 10(-7) M @entity3 . After pretreatment with 10 ng/ml of pertussis toxin, the McN A343-induced excitatory response in non-innervated myocytes was absent, thus suggesting that this response involved a pertussis toxin-sensitive G protein dependent pathway. McN A343 failed to stimulate @entity8 or @entity1 accumulation in non-innervated myocytes. These results demonstrate the following. (1) The muscarinic excitatory response is mediated via direct stimulation of a post-synaptic M1 receptor in non-innervated myocytes. (2) The excitatory response after innervation is related to the release of @entity4 , possibly through activation of muscarinic receptors located at the pre-synaptic sympathetic nerve terminals. (3) Sympathetic innervation prevents the functional expression of the post-synaptic myocardial M1 receptor. (4) The intracellular pathway for the post-synaptic M1 excitatory response involves a pertussis toxin-sensitive G protein, but does not depend on obvious changes in @entity1 or @entity7 hydrolysis.

title: An excitatory muscarinic response in neonatal XXXX ventricular myocytes and its modulation by sympathetic innervation.

answer: @entity0


abstract: Thirteen @entity0 affected by @entity5 were observed in the Pediatric Section of the Institute of Neurosurgery of the Catholic University of Rome in the last six years. Nine of them were operated because of an intractable @entity2 . Seven were males and 2 females; the age at operation ranged between 7 months and 11 years (mean: three years and five months); the follow-up period varied between 1 and 6 years (mean 3 years and 10 months). All the @entity0 had a clinical history of daily @entity2 not responsive to medical treatment; all of them presented with severely delayed @entity3 development. At neurological examination, six @entity0 showed a @entity1 of variable severity contralateral to the affected hemisphere and two @entity0 a severe @entity6 . The remaining @entity0 did not present with @entity1 . In all the cases the diagnosis had been obtained by CT scan and MRI. One of the cerebral hemispheres was abnormally enlarged with associated dilation of the lateral cerebral ventricle. The cortical architecture was obviously deranged with several areas of @entity4 of the gray substance suggesting an alteration of the neuronal cell migration. All the @entity0 underwent an extrathalamocaudato hemispherectomy. A post-operative ventriculo-peritoneal shunt was required in two cases. There were neither operative, nor late deaths. A dramatic reduction in the frequency and severity of @entity2 was observed in all but one of the @entity0 of the series.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Surgical treatment of epileptogenic XXXX ].

answer: @entity5


abstract: Frontal sections of the temporal lobe including the transentorhinal/entorhinal region, amygdala, and/or hippocampus from @entity0 adult brains are studied for cytoskeleton changes using immunostaining with the antibodies AT8 and Alz-50 and selective @entity1 impregnation methods for neurofibrillary changes of the Alzheimer type. For the purpose of correlation, the two methods are carried out one after the other on the same section. Layer pre-alpha in the transentorhinal/entorhinal region harbours nerve cells which are among the first nerve cells in the entire brain to show the development of neurofibrillary changes. This presents the opportunity for study of both early events in the destruction of the cytoskeleton in individual neurons, and to relate changes which occur in the neuronal processes in the absence of alterations in their immediate surroundings to those happening in the soma. Immunoreactions with the AT8 antibody in particular reveal a clear sequence of changes in the neuronal cytoskeleton. Group 1 neurons present initial cytoskeleton changes in that the soma, dendrites, and axon are completely marked by granular AT8 immunoreactive material. These neurons appear quite normal and turn out to be devoid of argyrophilic material when observed in @entity1 -stained sections. Group 2 neurons show changes in the cellular processes. The terminal tuft of the apical dendrite is replaced by tortuous varicose fibres and coarse granules. The distal portions of the dendrites are curved and show appendages and thickened portions. Intensely homogeneously immunostained rod-like inclusions are encountered in these thickened portions and in the soma. A number of these rod-like inclusions are visible after @entity1 staining, as well. Group 3 neurons display even more pronounced alterations of their distal--most dendritic portions. The intermediate dendritic parts lose immunoreactivity, but the soma is homogeneously immunostained. @entity1 staining reveals in most of the distal dendritic parts neuropil threads, and in the soma a classic @entity2 . Group 4 structures are marked by accumulations of coarse AT8-immunoreactive granules. @entity1 staining provides evidence that the fibrillary material has become an extraneuronal, "early" ghost tangle. Finally, group 5 structures present "late" ghost tangles in @entity1 -stained sections but fail to demonstrate AT8 immunoreactivity. It is suggested that the altered tau protein shown by the antibody AT8 represents an early cytoskeleton change which eventually leads to the formation of argyrophilic @entity2 and neuropil threads.

title: A sequence of cytoskeleton changes related to the formation of XXXX and neuropil threads.

answer: @entity2


abstract: BACKGROUND: Rapid eye movement (REM) @entity2 (RBD) has been described predominantly in elderly @entity0 and in association with @entity3 . But an increasing proportion of cases in recent reports and in clinical practice do not fit this description; thus we sought to describe a current RBD population and possibly identify new subgroups with RBD. METHODS: Records of 115 consecutive @entity0 with polysomnogram-confirmed RBD at an @entity1 were retrospectively reviewed. RESULTS: Male to female ratio was 2:1, and 1.25:1 for early-onset (age <50) cases. Mean age at diagnosis was 53.7  16.4years. Most (60%) cases were @entity3 was coincident primarily in older @entity0 . @entity4 was unexpectedly common in @entity0 (20%) particularly in the 30-49 age groups (40%). Antidepressant use was frequent (46.1%), especially in early-onset cases (57.8%). CONCLUSIONS: RBD is diagnosed more equally between @entity0 and @entity0 and in younger individuals than previously reported. While @entity3 is frequently co-incident with RBD in older @entity0 , most @entity0 and early-onset cases have "idiopathic" RBD. High prevalence of @entity4 among @entity0 with RBD suggests an intriguing link between @entity5 and RBD. A high rate of antidepressant use provides support for a potentially causal role for antidepressants in RBD.

title: Changing demographics in REM sleep behavior disorder: possible effect of XXXX and antidepressants.

answer: @entity4


abstract: OBJECTIVE: A study of immediate and long-term results with the self-expandable metallic stent (Wallstent), in the treatment of @entity2 in 25 @entity0 with non resectable @entity1 of the head of the pancreas was carried out. Stent placement was successful in all @entity0 . RESULTS: Complication rate was 4% (n = 1); one @entity0 had @entity4 after percutaneous catheter placement. There was no procedure related mortality (30-day mortality); hospital stay was 6, 7 days (2-12). Average survival was 6 months (+/- 2.97). Average patency of the initial stent lasted 5 months (+/- 2.01); comfort index was 83%. Five @entity0 required re-admission. Late complications were @entity3 in 2 and stent occlusion in 4. Disimpaction in one @entity0 and placement of additional stent (PAL-MAZ) in the remaining 3 @entity0 were performed. One @entity0 required surgical treatment; hepaticojejunostomy was performed. Elapse time between prostheses placement and stent occlusion was 3.4 months (2-4.5). CONCLUSIONS: We conclude that metallic stent placement has low morbidity without mortality and provide good quality of live. The most frequent late complication was prostheses obstruction.

title: [Self-expanding metallic endoprostheses in the palliative treatment of XXXX in nonresectable @entity1 of the head of the pancreas].

answer: @entity2


abstract: OBJECTIVE: A study of immediate and long-term results with the self-expandable metallic stent (Wallstent), in the treatment of @entity2 in 25 @entity0 with non resectable @entity1 of the head of the pancreas was carried out. Stent placement was successful in all @entity0 . RESULTS: Complication rate was 4% (n = 1); one @entity0 had @entity4 after percutaneous catheter placement. There was no procedure related mortality (30-day mortality); hospital stay was 6, 7 days (2-12). Average survival was 6 months (+/- 2.97). Average patency of the initial stent lasted 5 months (+/- 2.01); comfort index was 83%. Five @entity0 required re-admission. Late complications were @entity3 in 2 and stent occlusion in 4. Disimpaction in one @entity0 and placement of additional stent (PAL-MAZ) in the remaining 3 @entity0 were performed. One @entity0 required surgical treatment; hepaticojejunostomy was performed. Elapse time between prostheses placement and stent occlusion was 3.4 months (2-4.5). CONCLUSIONS: We conclude that metallic stent placement has low morbidity without mortality and provide good quality of live. The most frequent late complication was prostheses obstruction.

title: [Self-expanding metallic endoprostheses in the palliative treatment of @entity2 in nonresectable XXXX of the head of the pancreas].

answer: @entity1


abstract: OBJECTIVE: A crucial issue in youths with @entity3 , including @entity3 and @entity5 , is the refractoriness to treatments. A multimodal approach with individual therapy to improve social skills and self-control and family and school interventions is the best psychosocial treatment. Predictors of poor response to psychosocial treatment remain understudied. We aimed at exploring whether callous (lack of empathy and guilt) and unemotional (shallow emotions) (CU) trait and type of @entity1 (predatory vs. affective) can affect response to psychosocial treatment in referred youths with @entity3 . METHODS: The sample consisted of 38 youths (28 @entity0 and 10 @entity0 , age range: 6-14 years, mean age: 13.1        2.6 years) diagnosed as having @entity3 or @entity5 according to Diagnostic and Statistical Manual of @entity1 , 4th edition (DSM-IV) criteria and a clinical interview (Kiddie Schedule for @entity4 and @entity2 for School-Age @entity0 -Present and Lifetime Version), who completed a 6-month therapeutic program at our hospital. @entity0 were assessed according to severity and improvement (Clinical Global Impressions-Severity score [CGI-S] and CGI-Improvement score), functional impairment ( @entity0 's Global Assessment Scale [C-GAS]), type of @entity1 , predatory versus affective (Aggression Questionnaire), and CU dimension (Antisocial Process Screening Device and the Inventory of CU Traits). RESULTS: Among the 38 @entity0 , 21 (55.3%) were responders and 17 (44.7%) were nonresponders, according to CGI-Improvement score and CGI-S. Nonresponders were more impaired at the baseline according to CGI-S and C-GAS. Nonresponders presented higher scores of predatory @entity1 , whereas affective @entity1 did not differ between groups. Nonresponders presented higher scores in CU trait of Antisocial Process Screening Device and in Inventory of CU total score (callous trait), but these differences did not survive Bonferroni correction. CONCLUSIONS: Severity at the baseline and predatory @entity1 are negative predictors of psychosocial treatment, but the role of the callous trait needs more exploration in larger samples. Further research may increase our diagnostic and prognostic capacities, thus improving our treatment strategies.

title: Predictors of nonresponse to psychosocial treatment in @entity0 and adolescents with XXXX .

answer: @entity3


abstract: OBJECTIVE: A crucial issue in youths with @entity3 , including @entity3 and @entity5 , is the refractoriness to treatments. A multimodal approach with individual therapy to improve social skills and self-control and family and school interventions is the best psychosocial treatment. Predictors of poor response to psychosocial treatment remain understudied. We aimed at exploring whether callous (lack of empathy and guilt) and unemotional (shallow emotions) (CU) trait and type of @entity1 (predatory vs. affective) can affect response to psychosocial treatment in referred youths with @entity3 . METHODS: The sample consisted of 38 youths (28 @entity0 and 10 @entity0 , age range: 6-14 years, mean age: 13.1        2.6 years) diagnosed as having @entity3 or @entity5 according to Diagnostic and Statistical Manual of @entity1 , 4th edition (DSM-IV) criteria and a clinical interview (Kiddie Schedule for @entity4 and @entity2 for School-Age @entity0 -Present and Lifetime Version), who completed a 6-month therapeutic program at our hospital. @entity0 were assessed according to severity and improvement (Clinical Global Impressions-Severity score [CGI-S] and CGI-Improvement score), functional impairment ( @entity0 's Global Assessment Scale [C-GAS]), type of @entity1 , predatory versus affective (Aggression Questionnaire), and CU dimension (Antisocial Process Screening Device and the Inventory of CU Traits). RESULTS: Among the 38 @entity0 , 21 (55.3%) were responders and 17 (44.7%) were nonresponders, according to CGI-Improvement score and CGI-S. Nonresponders were more impaired at the baseline according to CGI-S and C-GAS. Nonresponders presented higher scores of predatory @entity1 , whereas affective @entity1 did not differ between groups. Nonresponders presented higher scores in CU trait of Antisocial Process Screening Device and in Inventory of CU total score (callous trait), but these differences did not survive Bonferroni correction. CONCLUSIONS: Severity at the baseline and predatory @entity1 are negative predictors of psychosocial treatment, but the role of the callous trait needs more exploration in larger samples. Further research may increase our diagnostic and prognostic capacities, thus improving our treatment strategies.

title: Predictors of nonresponse to psychosocial treatment in XXXX and adolescents with @entity3 .

answer: @entity0


abstract: In a multicenter study on the therapy of @entity2 , in 88 out of 297 @entity0 with primary advanced stages IIIB/IV, a failure to the treatment with the alternating chemotherapy COPP/ABVD +/- radiation was recorded. The cause of failure was as follows: @entity1 progression under current therapy ( @entity3 ) 23/88, partial response at the end of therapy (PR) 28/88, early nodal relapses 13/88, late nodal relapses 16/88, extranodal relapses 7/88, undetermined localization 1/88.36 months after manifestation of the failure to treatment, 45% of all @entity0 were still alive. In cases of primary @entity3 the prognosis was the worst of all. Only 1/23 of these @entity0 received a long-term continuous complete remission (cCR) with the salvage therapy. 11 @entity0 with only a nodal relapse received a cCR with irradiation alone. These cases could be regarded as low risk relapses. For the high risk relapse group (n = 57) an indication for high dose chemotherapy with subsequent autologous bone marrow transplantation (HDC/ABMT) would have been imperative, following the present-day definition. The probability of survival of these @entity0 who, however, only received a conventional salvage therapy was up to 38% (95% confidence interval 22-54%). Comparing these data with the literature our results seem not to be substantially worse than those for @entity0 who underwent HDC/ABMT. Only in a randomized comparison can the decision be made on whether HDC/ABMT would be superior to high dose conventional chemotherapy supported by hematopoietic growth factors. It is suggested that such a therapy study be performed as soon as possible.

title: Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of XXXX .

answer: @entity2


abstract: BACKGROUND: Previous reviews demonstrate uncertainty about the effectiveness of nurse-led interventions in the management of @entity2 . No specific reviews in @entity1 have been identified. We have systematically reviewed the evidence for effectiveness of nurse-led interventions for @entity0 with @entity1 . METHODS: In this systematic review and meta-analysis, searches of Medline, Embase, CINAHL and the Cochrane Central Trials register were undertaken to identify studies comparing any intervention conducted by nurses in managing @entity2 in @entity1 with usual doctor-led care. Additional citations were identified from papers retrieved and correspondence with authors. Outcome measures were absolute systolic and diastolic blood pressure, change in blood pressure, proportions achieving study target blood pressure and proportions prescribed anti- @entity2 medication. RESULTS:     Eleven studies were identified. Interventions included adoption of treatment algorithms, nurse-led clinics and nurse prescribing. Meta-analysis showed greater reductions in blood pressure in favour of any nurse-led interventions (systolic weighted mean difference -5.8 mmHg, 95% CI -9.6 to -2.0; diastolic weighted mean difference -4.2 mmHg, 95% CI -7.6 to -0.7) compared with usual doctor-led care. No overall superiority in achievement of study targets or in the use of medication was evident for any nurse-based interventions over doctor-led care. CONCLUSIONS: There is some evidence for improved blood pressure outcomes with nurse-led interventions for @entity2 in @entity0 with @entity1 compared with doctor-led care. Nurse-based interventions require an algorithm to structure care and there is some preliminary evidence for better outcomes with nurse prescribing. Further work is needed to elucidate which nurse-led interventions are most effective.

title: Nurse-led interventions used to improve control of high blood pressure in @entity0 with XXXX : a systematic review and meta-analysis.

answer: @entity1


abstract: BACKGROUND: Previous reviews demonstrate uncertainty about the effectiveness of nurse-led interventions in the management of @entity2 . No specific reviews in @entity1 have been identified. We have systematically reviewed the evidence for effectiveness of nurse-led interventions for @entity0 with @entity1 . METHODS: In this systematic review and meta-analysis, searches of Medline, Embase, CINAHL and the Cochrane Central Trials register were undertaken to identify studies comparing any intervention conducted by nurses in managing @entity2 in @entity1 with usual doctor-led care. Additional citations were identified from papers retrieved and correspondence with authors. Outcome measures were absolute systolic and diastolic blood pressure, change in blood pressure, proportions achieving study target blood pressure and proportions prescribed anti- @entity2 medication. RESULTS:     Eleven studies were identified. Interventions included adoption of treatment algorithms, nurse-led clinics and nurse prescribing. Meta-analysis showed greater reductions in blood pressure in favour of any nurse-led interventions (systolic weighted mean difference -5.8 mmHg, 95% CI -9.6 to -2.0; diastolic weighted mean difference -4.2 mmHg, 95% CI -7.6 to -0.7) compared with usual doctor-led care. No overall superiority in achievement of study targets or in the use of medication was evident for any nurse-based interventions over doctor-led care. CONCLUSIONS: There is some evidence for improved blood pressure outcomes with nurse-led interventions for @entity2 in @entity0 with @entity1 compared with doctor-led care. Nurse-based interventions require an algorithm to structure care and there is some preliminary evidence for better outcomes with nurse prescribing. Further work is needed to elucidate which nurse-led interventions are most effective.

title: Nurse-led interventions used to improve control of high blood pressure in XXXX with @entity1 : a systematic review and meta-analysis.

answer: @entity0


abstract: INTRODUCTION: Primary @entity8 of the small and large bowel presenting as a perforated viscus entity with @entity4 is extremely rare. A thorough literature review did not reveal any cases where @entity6 of the jejunum presented with perforation and @entity4 synchronously with @entity6 of the descending colon. CASE PRESENTATION: This report concerns a 64-year-old Caucasian @entity0 admitted with severe @entity5 and @entity3 . An emergency laparotomy revealed a large mass with perforation in the proximal jejunum with intense mesenteric thickening and lymphadenopathy. The descending colon was @entity1 and covered with fibrinous exudate. Histopathological examination of the resected segment of jejunum revealed a T cell @entity8 . On post-operative day 10, a computed tomography scan of our @entity0 's abdomen and pelvis showed leakage of contrast into the pelvis. Re-exploration revealed perforation of the descending colon. The histopathology of the resected colon also showed T cell @entity8 . Her post-operative course was complicated by acute renal and @entity7 . The @entity0 died on post-operative day 21. CONCLUSIONS: @entity6 has been reported to have a poor prognosis. The synchronous occurrence of lesions in the small intestine or colon is unusual, and impacts the prognosis adversely. Early diagnosis and treatment are important to improve the prognosis of @entity2 in @entity0 with @entity8 .

title: Synchronous perforation of XXXX of the small intestine and colon: a case report.

answer: @entity8


abstract: In this review it is concluded that @entity6 (T4), @entity5 (T3) and @entity4 (KI), singly or in combination, are all effective in reducing the @entity7 size, but there is insufficient evidence to prove which is the best (possibly the combination of T4 + KI?). Higher doses are more effective than smaller, but also lead to more side-effects. Thus, the optimal dose has yet to be found. The suppression of the @entity3 plays a major role in the treatment of @entity1 , but it is not definite that this is the only mechanism responsible for the beneficial effect of the agents mentioned. In view of the lack of better evidence, it is simply suggested that @entity1 in young @entity0 should be initially treated aggressively with 200 micrograms of T4/day or more for some months. If the @entity7 shrinks then the dose should be gradually decreased. If the @entity7 persists, it is futile to continue with large doses for more than 6-12 months. One may continue with smaller doses, maintaining the serum TSH in the low-normal range. The treatment of benign thyroid nodules with @entity6 is controversial. Probably @entity6 is beneficial in about a third of the cases. For both @entity1 and nodules, autonomy should be excluded before starting @entity6 treatment, and old age, @entity2 and a poor general condition are contraindications.

title: The medical treatment of XXXX : several questions remain.

answer: @entity1


abstract: Various dietary @entity10 have been linked to @entity0 and altered adipose metabolism; however, the influences of honey vs common sweeteners have not been fully explored. We hypothesized that in comparison with @entity5 , a honey-based diet would promote lower @entity6 , @entity7 , and related biomarkers (leptin, insulin, and adiponectin) as well as a better blood lipid profile. Thirty-six male @entity2 (228.1    12.5 g) were equally divided by weight into 2 groups (n = 18) and provided free access to 1 of 2 diets of equal energy densities differing only in a portion of the @entity9 . Diets contained 20% @entity9 (by weight of total diet) from either clover honey or @entity5 . After 33 days, epididymal fat pads were excised and weighed, and blood was collected for analyses of serum concentrations of lipids, @entity4 , and markers of @entity7 and @entity1 . Body @entity6 was 14.7% lower (P  <= .05) for @entity2 fed honey, corresponding to a 13.3% lower (P  <= .05) consumption of food/energy, whereas food efficiency ratios were nearly identical. Epididymal fat weight was 20.1% lower (P  <= .05) for @entity2 fed honey. Serum concentrations of @entity8 and leptin were lower (P  <= .05) by 29.6% and 21.6%, respectively, and non-high-density lipoprotein @entity3 was higher (P  <= .05) by 16.8% for honey-fed @entity2 . No significant differences in serum total @entity3 , high-density lipoprotein @entity3 , adiponectin, C-reactive protein, monocyte chemoattractant protein-1, @entity4 , or insulin were detected. These results suggest that in comparison with @entity5 , honey may reduce @entity6 and @entity7 , presumably due to lower food intake, and promote lower serum @entity8 but higher non-high-density lipoprotein @entity3 concentrations.

title: Honey promotes lower @entity6 , XXXX , and @entity8 than @entity5 in @entity2 .

answer: @entity7


abstract: Various dietary @entity10 have been linked to @entity0 and altered adipose metabolism; however, the influences of honey vs common sweeteners have not been fully explored. We hypothesized that in comparison with @entity5 , a honey-based diet would promote lower @entity6 , @entity7 , and related biomarkers (leptin, insulin, and adiponectin) as well as a better blood lipid profile. Thirty-six male @entity2 (228.1    12.5 g) were equally divided by weight into 2 groups (n = 18) and provided free access to 1 of 2 diets of equal energy densities differing only in a portion of the @entity9 . Diets contained 20% @entity9 (by weight of total diet) from either clover honey or @entity5 . After 33 days, epididymal fat pads were excised and weighed, and blood was collected for analyses of serum concentrations of lipids, @entity4 , and markers of @entity7 and @entity1 . Body @entity6 was 14.7% lower (P  <= .05) for @entity2 fed honey, corresponding to a 13.3% lower (P  <= .05) consumption of food/energy, whereas food efficiency ratios were nearly identical. Epididymal fat weight was 20.1% lower (P  <= .05) for @entity2 fed honey. Serum concentrations of @entity8 and leptin were lower (P  <= .05) by 29.6% and 21.6%, respectively, and non-high-density lipoprotein @entity3 was higher (P  <= .05) by 16.8% for honey-fed @entity2 . No significant differences in serum total @entity3 , high-density lipoprotein @entity3 , adiponectin, C-reactive protein, monocyte chemoattractant protein-1, @entity4 , or insulin were detected. These results suggest that in comparison with @entity5 , honey may reduce @entity6 and @entity7 , presumably due to lower food intake, and promote lower serum @entity8 but higher non-high-density lipoprotein @entity3 concentrations.

title: Honey promotes lower @entity6 , @entity7 , and @entity8 than @entity5 in XXXX .

answer: @entity2


abstract: Various dietary @entity10 have been linked to @entity0 and altered adipose metabolism; however, the influences of honey vs common sweeteners have not been fully explored. We hypothesized that in comparison with @entity5 , a honey-based diet would promote lower @entity6 , @entity7 , and related biomarkers (leptin, insulin, and adiponectin) as well as a better blood lipid profile. Thirty-six male @entity2 (228.1    12.5 g) were equally divided by weight into 2 groups (n = 18) and provided free access to 1 of 2 diets of equal energy densities differing only in a portion of the @entity9 . Diets contained 20% @entity9 (by weight of total diet) from either clover honey or @entity5 . After 33 days, epididymal fat pads were excised and weighed, and blood was collected for analyses of serum concentrations of lipids, @entity4 , and markers of @entity7 and @entity1 . Body @entity6 was 14.7% lower (P  <= .05) for @entity2 fed honey, corresponding to a 13.3% lower (P  <= .05) consumption of food/energy, whereas food efficiency ratios were nearly identical. Epididymal fat weight was 20.1% lower (P  <= .05) for @entity2 fed honey. Serum concentrations of @entity8 and leptin were lower (P  <= .05) by 29.6% and 21.6%, respectively, and non-high-density lipoprotein @entity3 was higher (P  <= .05) by 16.8% for honey-fed @entity2 . No significant differences in serum total @entity3 , high-density lipoprotein @entity3 , adiponectin, C-reactive protein, monocyte chemoattractant protein-1, @entity4 , or insulin were detected. These results suggest that in comparison with @entity5 , honey may reduce @entity6 and @entity7 , presumably due to lower food intake, and promote lower serum @entity8 but higher non-high-density lipoprotein @entity3 concentrations.

title: Honey promotes lower @entity6 , @entity7 , and @entity8 than XXXX in @entity2 .

answer: @entity5


abstract: Various dietary @entity10 have been linked to @entity0 and altered adipose metabolism; however, the influences of honey vs common sweeteners have not been fully explored. We hypothesized that in comparison with @entity5 , a honey-based diet would promote lower @entity6 , @entity7 , and related biomarkers (leptin, insulin, and adiponectin) as well as a better blood lipid profile. Thirty-six male @entity2 (228.1    12.5 g) were equally divided by weight into 2 groups (n = 18) and provided free access to 1 of 2 diets of equal energy densities differing only in a portion of the @entity9 . Diets contained 20% @entity9 (by weight of total diet) from either clover honey or @entity5 . After 33 days, epididymal fat pads were excised and weighed, and blood was collected for analyses of serum concentrations of lipids, @entity4 , and markers of @entity7 and @entity1 . Body @entity6 was 14.7% lower (P  <= .05) for @entity2 fed honey, corresponding to a 13.3% lower (P  <= .05) consumption of food/energy, whereas food efficiency ratios were nearly identical. Epididymal fat weight was 20.1% lower (P  <= .05) for @entity2 fed honey. Serum concentrations of @entity8 and leptin were lower (P  <= .05) by 29.6% and 21.6%, respectively, and non-high-density lipoprotein @entity3 was higher (P  <= .05) by 16.8% for honey-fed @entity2 . No significant differences in serum total @entity3 , high-density lipoprotein @entity3 , adiponectin, C-reactive protein, monocyte chemoattractant protein-1, @entity4 , or insulin were detected. These results suggest that in comparison with @entity5 , honey may reduce @entity6 and @entity7 , presumably due to lower food intake, and promote lower serum @entity8 but higher non-high-density lipoprotein @entity3 concentrations.

title: Honey promotes lower @entity6 , @entity7 , and XXXX than @entity5 in @entity2 .

answer: @entity8


abstract: Various dietary @entity10 have been linked to @entity0 and altered adipose metabolism; however, the influences of honey vs common sweeteners have not been fully explored. We hypothesized that in comparison with @entity5 , a honey-based diet would promote lower @entity6 , @entity7 , and related biomarkers (leptin, insulin, and adiponectin) as well as a better blood lipid profile. Thirty-six male @entity2 (228.1    12.5 g) were equally divided by weight into 2 groups (n = 18) and provided free access to 1 of 2 diets of equal energy densities differing only in a portion of the @entity9 . Diets contained 20% @entity9 (by weight of total diet) from either clover honey or @entity5 . After 33 days, epididymal fat pads were excised and weighed, and blood was collected for analyses of serum concentrations of lipids, @entity4 , and markers of @entity7 and @entity1 . Body @entity6 was 14.7% lower (P  <= .05) for @entity2 fed honey, corresponding to a 13.3% lower (P  <= .05) consumption of food/energy, whereas food efficiency ratios were nearly identical. Epididymal fat weight was 20.1% lower (P  <= .05) for @entity2 fed honey. Serum concentrations of @entity8 and leptin were lower (P  <= .05) by 29.6% and 21.6%, respectively, and non-high-density lipoprotein @entity3 was higher (P  <= .05) by 16.8% for honey-fed @entity2 . No significant differences in serum total @entity3 , high-density lipoprotein @entity3 , adiponectin, C-reactive protein, monocyte chemoattractant protein-1, @entity4 , or insulin were detected. These results suggest that in comparison with @entity5 , honey may reduce @entity6 and @entity7 , presumably due to lower food intake, and promote lower serum @entity8 but higher non-high-density lipoprotein @entity3 concentrations.

title: Honey promotes lower XXXX , @entity7 , and @entity8 than @entity5 in @entity2 .

answer: @entity6


abstract: Congenital dermal sinuses result from abnormal neurulation, and are uncommon. A spinal intramedullary abscess secondary to an infected @entity1 is very rare, and the functional prognosis is usually quite poor. We report on a 16-month-old @entity0 with @entity4 secondary to intramedullary abscesses because of a @entity2 associated with a dermal sinus. The abscesses were drained, and the @entity1 was removed. Antibiotics were administered for 6 weeks after neurosurgery. The @entity0 was followed at a pediatric rehabilitation department. After 1 year, he was able to walk quickly and had regained appropriate upper limb motor function for his age. However, bladder @entity5 persisted, requiring intermittent catheterization. This case highlights the importance of early diagnosis for surgical intervention and prolonged antibiotic therapy. Long-term follow-up by a multidisciplinary team allowed for the effective management of related neurologic, orthopedic, and @entity3 .

title: Recovery after XXXX caused by dermal sinus infection: intramedullary abscess and tetraparesis.

answer: @entity4


abstract: BACKGROUND: Hypoactivation of the inferior frontal gyrus during the perception of facial expressions has been interpreted as evidence for a deficit of the mirror neuron system in @entity0 with @entity3 . We examined whether this dysfunction persists in adulthood, and how brain activity in the mirror neuron system relates to social functioning outside the laboratory. METHODS: Twenty-one adult males with @entity1 and 21 typically developing subjects matched for age, sex, and IQ were scanned in three conditions: observing short movies showing facial expressions, performing a facial movement, and experiencing a disgusting taste. Symptom severity and level of social adjustment were measured with the Autism Diagnostic Observation Schedule and the Social Functioning Scale. RESULTS: Inferior frontal gyrus activity during the observation of facial expressions increased with age in subjects with @entity3 , but not in control subjects. The age-related increase in activity was associated with changes in gaze behavior and improvements in social functioning. These age-related neurocognitive improvements were not found in a group of individuals with @entity2 , who had comparable levels of social functioning. CONCLUSIONS: The results of this cross-sectional study suggest that mirror neuron system activity augments with age in @entity3 and that this is accompanied by changes in gaze behavior and improved social functioning. It is the first demonstration of an age-related neurocognitive improvement in @entity3 . Increased motor simulation may contribute to the amelioration in social functioning documented in adolescence and adulthood. This finding should encourage the development of new therapeutic interventions directed at emotion simulation.

title: Age-related increase in inferior frontal gyrus activity and social functioning in XXXX .

answer: @entity1


abstract: The primary constituent of the senile plaque core in @entity2 ( @entity2 ) is the beta-amyloid protein (beta A4). A discrete 11 @entity3 fragment of the beta A4, beta A4(25-35), has been implicated in mediating in vitro @entity4 and an inflammatory response surrounding senile plaques in @entity2 via interaction with the Serpin Enzyme Complex (SEC) receptor. Substance @entity7 ), a neuropeptide of the @entity6 family and a major mediator of @entity8 , shows sequence homology to beta A4(25-35) and has been shown to protect against the @entity4 of beta-amyloid. SP also competes with beta A4(25-35) for binding to the SEC-receptor. SP neurons have also been found to be depleted in @entity2 . Using a blister model of @entity0 in the @entity1 hind footpad, we have examined the effect of beta A4(25-35) and its interaction with SP in @entity1 skin microvasculature and determined age-related changes to these phenomena. In addition, pharmacological manipulation of these responses using SEC-receptor ligands (peptide 105Y and 105C) was also undertaken. Because of the evidence for co-existence and co-release of SP and @entity5 ( @entity5 ) from the peripheral terminals of sensory nerves, it was of interest to examine the interaction of @entity5 with beta A4(25-35) on @entity1 skin microvasculature. beta A4(25-35) (10 microM) was perfused over the base of a blister raised on the hind footpad of anaesthetised young and old @entity1 . This was followed by perfusion of SP (1 microM) or @entity5 (1 microM) after Ringer's solution. Relative blood flow was monitored using a Laser-Doppler Flowmeter.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Beta A4(25-35) modulates substance P effect on XXXX skin microvasculature in aged @entity1 : pharmacological manipulation using SEC-receptor ligands.

answer: @entity1


abstract: The primary constituent of the senile plaque core in @entity2 ( @entity2 ) is the beta-amyloid protein (beta A4). A discrete 11 @entity3 fragment of the beta A4, beta A4(25-35), has been implicated in mediating in vitro @entity4 and an inflammatory response surrounding senile plaques in @entity2 via interaction with the Serpin Enzyme Complex (SEC) receptor. Substance @entity7 ), a neuropeptide of the @entity6 family and a major mediator of @entity8 , shows sequence homology to beta A4(25-35) and has been shown to protect against the @entity4 of beta-amyloid. SP also competes with beta A4(25-35) for binding to the SEC-receptor. SP neurons have also been found to be depleted in @entity2 . Using a blister model of @entity0 in the @entity1 hind footpad, we have examined the effect of beta A4(25-35) and its interaction with SP in @entity1 skin microvasculature and determined age-related changes to these phenomena. In addition, pharmacological manipulation of these responses using SEC-receptor ligands (peptide 105Y and 105C) was also undertaken. Because of the evidence for co-existence and co-release of SP and @entity5 ( @entity5 ) from the peripheral terminals of sensory nerves, it was of interest to examine the interaction of @entity5 with beta A4(25-35) on @entity1 skin microvasculature. beta A4(25-35) (10 microM) was perfused over the base of a blister raised on the hind footpad of anaesthetised young and old @entity1 . This was followed by perfusion of SP (1 microM) or @entity5 (1 microM) after Ringer's solution. Relative blood flow was monitored using a Laser-Doppler Flowmeter.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Beta A4(25-35) modulates substance P effect on @entity1 skin microvasculature in aged XXXX : pharmacological manipulation using SEC-receptor ligands.

answer: @entity1